DNTH (Dianthus Therapeutics) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNTH Dianthus Therapeutics Inc DNTH
22 GF Score
Price $111.80
GF Value $3.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Dianthus Therapeutics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

DNTH
22GF Score
Dianthus Therapeutics Inc DNTH
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dianthus Therapeutics (DNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued. The current stock price of $111.80 is trading 2788.9% above its estimated GF Value™ of $3.87. GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.

Key valuation signals for DNTH:

  • Dividend-Payout-to-FFO:
  • GF Value™: $3.87 vs. price of $111.80 (2788.9% above fair value)
  • GF Score™: 22/100 with 6 warning signs

No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dianthus Therapeutics Business Description

Other Exchanges 87E:Germany
Address 7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score

Get the complete analysis for DNTH

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$111.80
Price
$3.87
GF Value